DR. ELIZABETH KILNER WICKWARE O.D.
Prescription History 1992017693
Optometrist in Chicago, IL


Quality Rating: 100 out of 100 score

NPI Status: Active since July 09, 2010

Contact Information

25 E. WASHINGTON STREET
SUITE 606
CHICAGO, IL
ZIP 60602
Phone: (312) 444-1111
Fax: (312) 444-1953

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. ELIZABETH KILNER WICKWARE O.D., an active Optometrist specialist practicing in Chicago, IL. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 159 documented patient claims. Among these therapy options, the most frequently utilized medication is Latanoprost, which accounts for 69 claims alone.

Medication Index

No matching medications currently found on file.

Brimonidine Tartrate

Generic Formulation: Brimonidine TartrateSpecialty: Optometry
Provider Metrics Summary
Total Claims 11
30-Day Fills 25.5
Days Supply 753
IL State Average Benchmarks
Peer Average Claims64.0
Peer Average 30-Day Fills122.1
Peer Average Days Supply3,538
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 82.8% less volume than the regional standard for practitioners inside IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $743.01 across this reporting matrix range.

Provider Avg Cost Per Claim

$67.55

State Avg Cost Per Claim

$41.21

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

This medication is used to treat open-angle glaucoma or high fluid pressure in the eye. Lowering high fluid pressure in the eye reduces the risk of vision loss, nerve damage, or blindness. This medication lowers pressure by allowing better fluid drainage from within the eye and also by reducing the amount of fluid formed in the eye. It is known as an alpha agonist. This drug is not recommended for use in children less than 2 years of age due to an increased risk of serious side effects such as very slowed breathing. Ask the doctor or pharmacist for details.

Dorzolamide Hcl

Generic Formulation: Dorzolamide HclSpecialty: Optometry
Provider Metrics Summary
Total Claims 21
30-Day Fills 33.8
Days Supply 1,013
IL State Average Benchmarks
Peer Average Claims53.0
Peer Average 30-Day Fills108.8
Peer Average Days Supply3,249
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 60.4% less volume than the regional standard for practitioners inside IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $531.15 across this reporting matrix range.

Provider Avg Cost Per Claim

$25.29

State Avg Cost Per Claim

$29.18

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Dorzolamide is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. It belongs to a class of drugs known as carbonic anhydrase inhibitors.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Optometry
Provider Metrics Summary
Total Claims 69
30-Day Fills 142.4
Days Supply 4,161
IL State Average Benchmarks
Peer Average Claims141.0
Peer Average 30-Day Fills260.8
Peer Average Days Supply7,448
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 51.1% less volume than the regional standard for practitioners inside IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,798.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$26.06

State Avg Cost Per Claim

$23.58

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Timolol Maleate

Generic Formulation: Timolol MaleateSpecialty: Optometry
Provider Metrics Summary
Total Claims 58
30-Day Fills 129.2
Days Supply 3,877
IL State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills57.0
Peer Average Days Supply1,697
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 81.3% higher than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $843.79 across this reporting matrix range.

Provider Avg Cost Per Claim

$14.55

State Avg Cost Per Claim

$561.76

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A beta-adrenergic antagonist that is similar in action to PROPRANOLOL; the levo-isomer is more active. Timolol has been proposed as an anti-hypertensive, anti-arrhythmic, anti-angina, and anti-glaucoma agent. It is also used in the treatment of MIGRAINE DISORDERS and tremor.

Therapeutic Applications

This medication is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. ELIZABETH KILNER WICKWARE O.D. provides transparency into local medical care patterns within Chicago, IL.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Optometrist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.